Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...

Find all the latest Q2 results 2025 updates of Bharti Airtel, Titan Company, Power Grid Corporation of India, Ambuja Cements, ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

Biocon's Q2 preview highlights strong biosimilar growth, while generics face challenges amid mixed sector performance ahead of November 11 results.

Our Bureau, Bengaluru Monday, October 20, 2025, 15:20 Hrs [IST] Biocon Biologics, a global leader in biosimilars and the world ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Gov. Gavin Newsom announced Thursday he is rolling out an effort to lower the price of insulin to $11. CalRx, the state-run program that aims to lower the cost of insulin and other medications, would ...

SACRAMENTO, California — California will start selling low-cost insulin in January, becoming the first state in the nation to bypass Big Pharma with its own supply of the expensive diabetes drug and ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

California has launched a program to manufacture and sell lower-cost insulin to people with diabetes. State officials say ...

China is advancing its “health silk road” in Africa by initiating major offshore projects to manufacture essential medicines, such as insulin and antiretrovirals. Nigeria is set to produce ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...